{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Categorization of Websites using LSTM\n",
    "\n",
    "In this notebook, let us discuss in detail how to build an RNN model for classifying text in python using the keras framework.\n",
    "\n",
    "\n",
    "## Table of Contents\n",
    " - Problem Statement\n",
    " - Data set\n",
    " - Preprocessing\n",
    "     - Cleaning\n",
    "     - Label Encoding\n",
    "     - Validation split\n",
    "     - Padding\n",
    " - Model building\n",
    "     - LSTM\n",
    "     - GRU\n",
    "     - Comparison: LSTM vs GRU \n",
    "\n",
    "### Problem Statement\n",
    "\n",
    "- Classification of Web page content is vital to many tasks in Web information retrieval such as maintaining Web directories and focused crawling. \n",
    "- The uncontrolled nature of Web content presents additional challenges to Web page classification as compared to traditional text classification since there can be many kind of noise present in the data apart from text.\n",
    "- The objective is to build a model that classifies the webpages into different tags based on the text in the webpage."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Import required libraries**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package stopwords to /home/sanad/nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import nltk\n",
    "from nltk.corpus import stopwords\n",
    "import re\n",
    "nltk.download('stopwords')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### About the Data set\n",
    "- Let us look at the first 5 rows "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(53447, 3)"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "new_train=pd.read_csv(\"web_categ_final.csv\")\n",
    "new_train.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Webpage_id</th>\n",
       "      <th>Tag</th>\n",
       "      <th>text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>news</td>\n",
       "      <td>b'    Skip to main content                    ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>news</td>\n",
       "      <td>b'    Skip to main content                    ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>news</td>\n",
       "      <td>b'    Skip to main content                    ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>news</td>\n",
       "      <td>b\"    Skip to main content                    ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>news</td>\n",
       "      <td>b\"    Skip to main content                    ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Webpage_id   Tag                                               text\n",
       "0           1  news  b'    Skip to main content                    ...\n",
       "1           2  news  b'    Skip to main content                    ...\n",
       "2           3  news  b'    Skip to main content                    ...\n",
       "3           4  news  b\"    Skip to main content                    ...\n",
       "4           5  news  b\"    Skip to main content                    ..."
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "new_train.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Let us look at the frequency of each label"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "others            17417\n",
       "news               7992\n",
       "publication        7705\n",
       "profile            5196\n",
       "conferences        4666\n",
       "forum              4503\n",
       "clinicalTrials     2839\n",
       "thesis             1800\n",
       "guidelines         1329\n",
       "Name: Tag, dtype: int64"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "new_train['Tag'].value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Preprocessing\n",
    "\n",
    "1.The raw data is messy. It contains links, non ascii characters, punctuations, numbers, extra spaces, etc.\n",
    "\n",
    "2.So, Data Pre-processing is the most important step prior to the model building in which we remove all the unnecessary qualities from the data.\n",
    "\n",
    "\n",
    "### 1. Cleaning\n",
    "\n",
    "**Steps** \n",
    "\n",
    "1.Convert to lowercase\n",
    "\n",
    "2.Removal of links\n",
    "\n",
    "3.Removal of text inside {} and ()\n",
    "\n",
    "4.Removal of special characters, punctuations, numbers\n",
    "\n",
    "5.Removal of short words"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      " b'    Skip to main content                                    Twitter  LinkedIn      Search           Top Menu    DDF 2017    FierceBiotech    Jobs    Resources    Events    Subscribe                  Main navigation    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory        Main navigation - Mobile    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory                    Marketing          Tecfidera, Gilenya and Aubagio\\'s 3-way battle for MS share is about to heat up         by Tracy Staton | Oct 31, 2016 6:54am                        Multiple sclerosis drugmakers are in a fix: These days, the U.S. market isn\\xe2\\x80\\x99t delivering the kind of growth that had been fueling big increases in sales.  For high-flying pills from Biogen (Tecfidera) and Novartis (Gilenya), that could mean an unwelcome comedown. It definitely means\\xc2\\xa0 the coming market-share battle will grow even more competitive than before. If the quickest way to grow sales is to steal share, you can bet Tecfidera and Gilenya--and their up-and-coming rival med from Sanofi, Aubagio--will be working hard to do just that.  Thing is, Biogen isn\\xe2\\x80\\x99t on that sort of growth trajectory. It\\xe2\\x80\\x99s the market leader--with 51% share of the oral market and 20% of MS overall, as EVP Michel Vounatsos hastened to point out during the company\\xe2\\x80\\x99s earnings call with analysts last week. But Tecfidera\\xe2\\x80\\x99s 10% growth during the quarter largely depended on price increases , the company disclosed in a securities filing the next day.  Gilenya, on the other hand, grew by 15%, and in its earnings announcement , the Swiss drugmaker said that growth wasn\\xe2\\x80\\x99t based on price, but volume. That\\xe2\\x80\\x99s not to say Gilenya doesn\\xe2\\x80\\x99t have some troubling signs in its Q3 stats; pharma chief Paul Hudson said script numbers have been \\xe2\\x80\\x9cbroadly flat but a little bit down\\xe2\\x80\\x9d--which suggests the overall market slowdown hasn\\xe2\\x80\\x99t been without its effect on Gilenya, too.  Neither Biogen nor Novartis plans to stick with the status quo. Biogen is grappling with Tecfidera\\xe2\\x80\\x99s gastrointestinal side effects, and various MS specialists are working on ways to manage that; 22% of Tecfidera patients quit because of GI issues, and keeping patients on therapy would obviously help sales.  The Tecfidera team is pilot-testing a new \\xe2\\x80\\x9cengagement model\\xe2\\x80\\x9d at top treatment centers, with plans to roll it out by January. \\xe2\\x80\\x9cThe team in the U.S. is all up and running,\\xe2\\x80\\x9d Vounatsos said during the call. \\xe2\\x80\\x9cI\\xe2\\x80\\x99m very pleased to see the perception improvement, and now we have to continue to execute.\\xe2\\x80\\x9d  On the advertising side, Biogen recently backed off a TV campaign that had stirred up some controversy in the MS community, and the company said at the time that it didn\\xe2\\x80\\x99t plan more television in the immediate future, though it is running other DTC promos.  Novartis is running with its Hey MS, Take This! campaign for Gilenya, which launched in 2014 and has since won kudos--and made inroads--particularly with its digital and social media work. Besides print and web video, the campaign invites patients to \\xe2\\x80\\x9ctell relapsing MS exactly where to go,\\xe2\\x80\\x9d and many have, both on the campaign\\xe2\\x80\\x99s website and via social media. They\\xe2\\x80\\x99ve also shared what they do to manage their MS.       Novartis apparently believes that Gilenya DTC and salesforce work, coupled with a steady stream of new data, will keep the brand\\xe2\\x80\\x99s volume growing enough to avoid using price as a driver. The company has \\xe2\\x80\\x9csome sensible plans\\xe2\\x80\\x9d for growth, without \\xe2\\x80\\x9ca big impact ... on price,\\xe2\\x80\\x9d Hudson said during the Q3 call. \\xe2\\x80\\x9cWe are ...\\xc2\\xa0 looking forward to the energy into Q4,\\xe2\\x80\\x9d he said.  Meanwhile, the big leaper of the quarter was Aubagio, Sanofi\\xe2\\x80\\x99s slow-to-start entry in the class. Sales of that drug grew by almost 50% to 334 million euros during the quarter--and that was driven by growth in the U.S. Its 9-month revenue amounted to 928 million euros, a 57% hike. The French drugmaker quickly bragged that Aubagio is the \\xe2\\x80\\x9cfastest-growing oral disease modifying therapy\\xe2\\x80\\x9d in MS, with a U.S. share of 9%--far far below Tecfidera\\xe2\\x80\\x99s, but rising. This time last year, Sanofi was happy to report it had captured a 6% share.  What\\xe2\\x80\\x99s spurring Aubagio on? The company has been running a campaign with Revenge star Madeleine Stowe since late 2014, for one; the actor has been traveling across the U.S. doing awareness events. The Lights! Camera! Take Action! partnership most recently rolled out a series of \\xe2\\x80\\x9cwebisodes\\xe2\\x80\\x9d featuring Stowe in interviews with MS patients--a common theme in awareness campaigns--but also with nurses, physical therapists and others with advice for MS patients and their caregivers.       The drug\\'s brand website also has a share-your-story channel, and Sanofi has put other promo work under a tagline, \"Aubagio quiets MS.\" The company\\xc2\\xa0has set out a goal of \\xe2\\x82\\xac2 billion in sales by 2020 for its entire franchise; if Aubagio and its fellow med Lemtrada keep delivering as they are, the company could actually hit that target sooner. \"In MS, we continued to gain share, and sales from the franchise are now approaching \\xe2\\x82\\xac2 billion on an annualized basis,\" CEO Olivier Brandicourt said during the company\\'s Q3 call.  Biogen\\xe2\\x80\\x99s Vounatsos may have summed it up for the entire oral market when he pledged to fight the good fight on Tecfidera last week. \\xe2\\x80\\x9cThe base of the market is certainly lower than what we have estimated in our assumptions, but it\\'s not an excuse for not increasing share,\\xe2\\x80\\x9d he said.  There\\xe2\\x80\\x99s a confounding factor, however: The group of oral treatments may get some unwanted rivals in a few years. Novartis could face earlier-than-expected Gilenya generics, thanks to some recent patent decisions. As early as 2019, in fact--and that would give these three meds just a few more years to divvy up share just among themselves. Add to that the payer pressure that\\'s increasingly a problem, and the price-increase growth option looks even less likely.  Related Articles: Biogen\\xe2\\x80\\x99s Tecfidera, Amgen\\xe2\\x80\\x99s Enbrel tell a tale of pricing power and weakness Novartis could snag a blockbuster MS market all for itself, just in time to fight Gilenya generics Biogen\\'s controversial Tecfidera ad is about to meet its end Biogen sees new Tecfidera buzz as DTC, marketing push kicks in Buoyed by rising tide of Aubagio scripts, Sanofi aims for \\xe2\\x82\\xac2B in MS sales Early Gilenya generics now spell trouble for rival MS drugs    Read more on   multiple sclerosis , drug launch , generics , payer , Sanofi , Aubagio , Tecfidera , Biogen , Novartis , Gilenya                                           Popular Content   Pfizer puts hemophilia spin on ultrapopular Minecraft to educate young patients Sep 06, 2017  Takeda, Johnson & Johnson and more join Clara Health\\'s Boston-based patient empowerment push Sep 06, 2017  Empathy at work: GlaxoSmithKline extends Excedrin Migraine campaign to include sufferers on the job Sep 04, 2017  What\\'s the world\\'s best pharma market? To Allergan\\'s CEO, that one\\'s easy Aug 07, 2017  Roche nets new Actemra nod to treat deadly CAR-T response Sep 01, 2017     About the Author        Tracy Staton  Editor-in-Chief  tracy@fiercemarkets.com  https://twitter.com/TracyStaton                                  \\xe2\\x80\\x8b   Home  Subscribe  Manage Newsletter Subscriptions  Advertise  RSS  Privacy  About Us  Contact    \\xc2\\xa9 2017 Questex LLC. All rights reserved.  275 Grove Street, Suite 2-130 Newton, MA 02466  Reproduction in whole or part is prohibited.                        '\n",
      "\n",
      "\n",
      " b'    Skip to main content                                    Twitter  LinkedIn      Search           Top Menu    DDF 2017    FierceBiotech    Jobs    Resources    Events    Subscribe                  Main navigation    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory        Main navigation - Mobile    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory                    Pharma          Novo equipped to weather the storm in the U.S. diabetes market, CEO says         by Eric Palmer | Oct 28, 2016 10:02am                        Novo Nordisk is facing a future of price decreases and pressured profits in the U.S., but the organization is equipped\\xc2\\xa0to thrive in such a hostile pricing environment, CEO Lars S\\xc3\\xb8rensen insists. It will do that by calling on its experiences jousting with price regulators\\xc2\\xa0in Europe.  \\xe2\\x80\\x9cWe have been used to operating in such an environment in the EU, and in Japan,\\xe2\\x80\\x9d S\\xc3\\xb8rensen insisted today, pointing to two markets that for years have been tight-fisted in reimbursements while the U.S. was a haven of growth.  The answer came in response to a question posed point-blank to execs today during a call with analysts, as they reported that Novo\\'s ($NOVO)\\xc2\\xa0operating profit fell 1% in Q3 2016 and for the year is now expected to be half of what the company had projected 8 months ago, 5% instead of 10%. That news whacked share prices 15% in early trading. An analyst wanted to know if the Danish company required a different structure and different people to make money in a tough market. S\\xc3\\xb8rensen said that it did, insisting its commitment to the U.S. market was steadfast.  But S\\xc3\\xb8rensen will not have to fight the battles there any longer. He is stepping down at year-end and is being replaced by Lars Fruergaard Jorgensen , who\\'s currently the company\\'s EVP and head of corporate development.  Jorgensen acknowledged that the U.S. market will be extremely tough in the near term, but growth in China and other parts of the world will help compensate until the U.S. market starts to turn\\xc2\\xa0around in 2018, he said.  \\xe2\\x80\\x9cWhen we look across the world, the change in the operating environment is mainly in U.S. \\xe2\\x80\\xa6 We have to acknowledge we are not fully satisfied with the U.S. operations,\\xe2\\x80\\x9d Jorgensen said. But the company has the right portfolio for a turnaround there and with \\xe2\\x80\\x9ca restructuring in the U.S. operations, we will get a grip,\\xe2\\x80\\x9d Jorgensen insisted.  That restructuring was announced in September, with 1,000 people worldwide being let go due to cut costs. Cuts will also come in R&D, although R&D spending will remain at about 13%, as the Danish drugmaker focuses on more innovative products that payers will cover. The job cuts will also hit the headquarters in Bagsvaerd, near Copenhagen, as well as the company\\xe2\\x80\\x99s commercial operations worldwide.  There were some bright spots in today\\xe2\\x80\\x99s report. Tresiba, the company\\xe2\\x80\\x99s new longer-acting product, grew 187% and sales of its GLP-1 drug, Victoza, were up 13%. There is also Saxenda, Novo\\xe2\\x80\\x99s entry in the weight-control market. In fact, Bernstein analyst Ronny Gal told investors today that\\xc2\\xa0Saxenda accounted for 16% of growth in the first 9 months and that it will be an \\xe2\\x80\\x9cincreasingly important product\\xe2\\x80\\x9d going forward.  Like Novo, Gal told his clients that he expects strong growth going forward for\\xc2\\xa0GLP-1 meds, a market Novo shares with competitors. Novo and Sanofi are both developing new weekly combo meds in that category, although both have had consideration of their drugs delayed by the FDA.  He says it is reasonable to assume such growth\\xc2\\xa0but points out\\xc2\\xa0that Novo was not considering the \"worst case scenario.\\xe2\\x80\\x9d While Novo execs said they did not expect payers to go to a \\xe2\\x80\\x9csingle source market\\xe2\\x80\\x9d for GLP-1 drugs to extract deeper discounts, Gal does not rule it out. \\xe2\\x80\\x9cIf there is another cut to expectations this is likely where it comes from,\\xe2\\x80\\x9d he told investors, suggesting that a really rocky midterm market for Novo could still get rockier.  - here\\xe2\\x80\\x99s the earnings release  Related Articles: U.S. payer pressures force Novo Nordisk to cut loose 1,000 staffers Novo Nordisk CEO Sorensen to step down early as pricing pressures mount Novo Nordisk stokes GLP-1 hopes as weekly semaglutide slashes heart risks by 26% Express Scripts bars new launches from Lilly, Merck and shuts out Novo for 2017 Sanofi\\'s Adlyxin holds a slight safety edge over Novo\\'s Victoza, report finds That head start for Novo\\'s combo med Xultophy? The FDA delayed it instead    Read more on   financials , Novo Nordisk                                           Popular Content   Teva lures Lundbeck chief Schultz with $52M package that makes him among pharma\\'s top paid Sep 12, 2017  Alexion plots hundreds of layoffs, HQ move in sweeping corporate revamp Sep 12, 2017  FDA says Tecentriq won\\'t lose its bladder cancer nod despite phase 3 failure, Roche reports Sep 12, 2017  ESMO need-to-know: Keytruda misses head and neck; Tagrisso wins; plus Lilly, BMS and more Sep 11, 2017  Teva makes good on asset-sale vows with $1.1B contraceptive sale Sep 11, 2017     About the Author        Eric Palmer  Senior Editor  epalmer@fiercemarkets.com                                   \\xe2\\x80\\x8b   Home  Subscribe  Manage Newsletter Subscriptions  Advertise  RSS  Privacy  About Us  Contact    \\xc2\\xa9 2017 Questex LLC. All rights reserved.  275 Grove Street, Suite 2-130 Newton, MA 02466  Reproduction in whole or part is prohibited.                        '\n",
      "\n",
      "\n",
      " b'    Skip to main content                                    Twitter  LinkedIn      Search           Top Menu    DDF 2017    FierceBiotech    Jobs    Resources    Events    Subscribe                  Main navigation    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory        Main navigation - Mobile    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory                    Pharma          Another exec departs troubled Endo--and this time, it\\'s for another drugmaker         by Carly Helfand | Oct 21, 2016 7:05am                        Endo\\xe2\\x80\\x99s ( $ENDP ) CEO exodus is continuing. Its CFO is following its CEO out the door--to work for another drugmaker, no less.  Thursday, the Dublin company announced that financial chief, Suketu Upadhyay, would be hitting the road to \\xe2\\x80\\x9cassume a senior-level finance position at a global biopharmaceutical company.\\xe2\\x80\\x9d Blaise Coleman, Endo\\'s SVP of Global Finance Operations, will step up in his stead while Endo searches for a permanent replacement.  It\\xe2\\x80\\x99s been a rocky financial year for Endo, which--much like Valeant ( $VRX ), a company whose footsteps it\\xe2\\x80\\x99s seemingly been following in for years--slashed its Q2 guidance earlier this year,\\xc2\\xa0and the 40% share-price decline that ensued locked up the stock\\xe2\\x80\\x99s second-worse daily performance ever. It also cut 740 jobs.\\xc2\\xa0The company blamed new rivals on the market, greater-than-expected generics price erosion, regulatory delays and more for a revised revenue forecast that hit well below analyst expectations.  But new Endo skipper Paul Campanelli--the former Par chief who relieved Endo\\xe2\\x80\\x99s Rajiv De Silva late last month--was quick to point out that the company recently reaffirmed its third-quarter and full-year predictions, an attempt to reassure investors that more bad news wasn\\xe2\\x80\\x99t on the way.  What may be on the way for the troubled drugmaker, though? Divestments. Late in June, Reuters reported that Endo--like Valeant--was looking for asset sales that could help pay down its acquisition-fueled debt mountain.\\xc2\\xa0 And Thursday, Campanelli noted that the specialty pharma would \\xe2\\x80\\x9ccomplete a product-by-product assessment of our portfolio and further sharpen Endo\\'s strategy and operational focus.\"  And analysts are already talking up potential takers. Earlier this week, RBC Capital Markets\\xe2\\x80\\x99 Randall Stanicky wrote in a note to investors that Endo\\xe2\\x80\\x99s pain business could make a good buy for California\\xe2\\x80\\x99s Depomed ( $DEPO ), which may scout\\xc2\\xa0for M&A now that it\\xe2\\x80\\x99s settled a proxy dispute with activist investor Starboard Value.  - read Endo\\'s release  Special Report:  The most influential people in biopharma today - 2014 - J. Michael Pearson - Valeant  Related Articles: Depomed strikes unexpected deal with activist Starboard, adding J&J, Abbott vets to board It\\'s out with the old CEO, in with the new as Endo\\'s Campanelli takes De Silva\\'s seat Endo keeps up its Valeant act with asset-sale talks Endo\\'s Valeant-esque guidance-slashing decimates shares Valeant investors, shocked by lightweight guidance, aren\\'t buying CEO Pearson\\'s recovery plans Endo scoops up Par Pharma for $8B to gain ground in injectables Is Endo on the verge of a Valeant-type acquisition binge?    Read more on   Endo                                           Popular Content   Lilly to cut 3,500 jobs, take a $1.2B hit as it aims for $500M in savings Sep 07, 2017  After Keytruda deaths, FDA hits pause on Bristol-Myers Squibb\\'s Opdivo myeloma trials Sep 07, 2017  Survival win has Bristol-Myers\\' Opdivo-Yervoy combo looking better as first-line kidney cancer treatment Sep 07, 2017  Novo to pay nearly $60M to settle Victoza marketing suits with DOJ, whistleblowers Sep 06, 2017  Senator\\xe2\\x80\\x99s report documents deceit by former employees of embattled Insys Sep 07, 2017     About the Author        Carly Helfand  Senior Editor  chelfand@fiercemarkets.com                                   \\xe2\\x80\\x8b   Home  Subscribe  Manage Newsletter Subscriptions  Advertise  RSS  Privacy  About Us  Contact    \\xc2\\xa9 2017 Questex LLC. All rights reserved.  275 Grove Street, Suite 2-130 Newton, MA 02466  Reproduction in whole or part is prohibited.                        '\n",
      "\n",
      "\n",
      " b\"    Skip to main content                                    Twitter  LinkedIn      Search           Top Menu    DDF 2017    FierceBiotech    Jobs    Resources    Events    Subscribe                  Main navigation    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory        Main navigation - Mobile    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory                    Pharma          Would Teva buy Korea's Celltrion to beef up in biosimilars? It wouldn't say no         by Carly Helfand | Oct 17, 2016 5:56am                        Earlier this month, Teva agreed to pick up U.S. and Canadian rights to a pair of biosims from Korea\\xe2\\x80\\x99s Celltrion. But it might not stop with just two.  The generics giant may\\xc2\\xa0consider purchasing the Korean drugmaker itself, a Teva spokesman told Korean news source The Investor .  \\xe2\\x80\\x9cWe will continue to investigate such opportunities as we balance risk and seek complementary skills in our partners,\\xe2\\x80\\x9d he said.  It\\xe2\\x80\\x99s not the first time the idea has come up. Back in early 2014, when Celltrion was planning to sell a controlling stake in the company, Teva\\xe2\\x80\\x99s name popped up in deal rumors--along with those of peers AstraZeneca and Roche.  Why all the interest? Celltrion\\xe2\\x80\\x99s biosim plans are beginning to come to fruition. Along with partner Pfizer, it\\xc2\\xa0already boasts an FDA-approved copy of Johnson & Johnson blockbuster Remicade waiting for the green light to launch in the U.S.  And there\\xe2\\x80\\x99s more where that came from. It\\xe2\\x80\\x99s working on versions\\xc2\\xa0of Roche oncology giants Rituxan and Herceptin, too--and it granted Teva North American rights to those biosims in a $160 million pact sealed in early October.  Teva CEO Erez Vigodman in particular has highlighted biosimilars as a key component of the Israeli drugmaker's\\xc2\\xa0strategy. But the company has already struck out once in the field: In 2013, one-time biosim partner Lonza backed out of the pair\\xe2\\x80\\x99s 2009 agreement after development and marketing costs piled up.  Meanwhile, Vigodman has also been talking up branded buys since Teva wrapped up its\\xc2\\xa0$40 billion Allergan generics\\xc2\\xa0buyout. Teva will be looking out for \\xe2\\x80\\x9cattractive specialty assets, or branded drug assets or pipeline assets\\xe2\\x80\\x9d that fit in with the therapeutic areas it\\xe2\\x80\\x99s already tackling, including pain, neurodegenerative disease and respiratory disorders, Vigodman said in August.  Related Articles: Teva ponies up $160M-plus for marketing rights to Celltrion's Rituxan, Herceptin biosims Teva shares rival Mylan's pain as both hit two-year lows How can Teva buck industry trends for 5% yearly generics growth? Launches--and lots of them Can Celltrion's Remicade biosim repeat its EU market-share steal in the U.S.? Roche, Teva and AstraZeneca are all said to be in the mix to buy Celltrion Teva, Lonza end biosimilars joint venture as the copycat crowd thins    Read more on   M&A , Teva Pharmaceutical , Celltrion , Rituxan , Remicade , Roche , Pfizer                                           Popular Content   Lilly to cut 3,500 jobs, take a $1.2B hit as it aims for $500M in savings Sep 07, 2017  After Keytruda deaths, FDA hits pause on Bristol-Myers Squibb's Opdivo myeloma trials Sep 07, 2017  Survival win has Bristol-Myers' Opdivo-Yervoy combo looking better as first-line kidney cancer treatment Sep 07, 2017  Novo to pay nearly $60M to settle Victoza marketing suits with DOJ, whistleblowers Sep 06, 2017  Senator\\xe2\\x80\\x99s report documents deceit by former employees of embattled Insys Sep 07, 2017     About the Author        Carly Helfand  Senior Editor  chelfand@fiercemarkets.com                                   \\xe2\\x80\\x8b   Home  Subscribe  Manage Newsletter Subscriptions  Advertise  RSS  Privacy  About Us  Contact    \\xc2\\xa9 2017 Questex LLC. All rights reserved.  275 Grove Street, Suite 2-130 Newton, MA 02466  Reproduction in whole or part is prohibited.                        \"\n",
      "\n",
      "\n",
      " b\"    Skip to main content                                    Twitter  LinkedIn      Search           Top Menu    DDF 2017    FierceBiotech    Jobs    Resources    Events    Subscribe                  Main navigation    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory        Main navigation - Mobile    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory                    Marketing          Restasis-maker Allergan recruits actress Marisa Tomei to drive dry eye awareness         by Beth Snyder Bulik | Oct 17, 2016 8:18am                        Is there an Oscar for best dry eye awareness performance in pharma? Actress\\xc2\\xa0Marisa Tomei is speaking up about the disease\\xc2\\xa0as Allergan's spokesperson\\xc2\\xa0for its branded Restasis marketing, while\\xc2\\xa0Shire has tapped\\xc2\\xa0actress Jennifer Aniston to front its disease awareness TV campaign.\\xc2\\xa0Tomei signed on as\\xc2\\xa0an ambassador for Restasis in July,\\xc2\\xa0talking to news and TV media outlets about her own experience with the disease, and Aniston joined Shire's unbranded effort in August.  Tomei\\xc2\\xa0also teamed up with Guide Dogs for the Blind and will contribute $1 for every person who takes the Restasis\\xc2\\xa0dry eye quiz on its website through the end of the year. So far, more than 40,000 people have done so. Traffic to the Restasis website has also increased by 50% since the campaign began, Herm Cukier, senior vice president for U.S. eye care at Allergan, told FiercePharma .  Restasis is the market share leader in dry eye prescription treatments, launched first in 2003. But it recently got its first category competition with\\xc2\\xa0Shire\\xe2\\x80\\x99s launch of Xiidra. To promote the newer drug, Shire is running two ad campaigns, the unbranded dry eye disease awareness campaign featuring Aniston, and another branded Xiidra campaign that began in September.  While the two compete in the dry eye treatment market, they have different indications.\\xc2\\xa0Xiidra is approved for dry eye disease, while Restasis\\xe2\\x80\\x99 indication is for increasing tear production. A Bernstein analyst noted recently that while Shire has the full dry eye label advantage, Allergan \\xe2\\x80\\x9cenjoys the power of incumbency,\\xe2\\x80\\x9d including contracts, sales and an established patient pool.  Cukier said that even after Restasis\\xe2\\x80\\x99 years on the market, awareness about dry eye is still needed for several reasons:\\xc2\\xa0It\\xe2\\x80\\x99s not an obvious condition with symptoms that can often also be attributed to other causes; modern lifestyles that include increased screen time can exacerbate the condition; and increasing innovation in the category will open up different options for different types of dry eye conditions.  He noted Allergan\\xe2\\x80\\x99s own pipeline of treatments, which includes a recent filing for \\xe2\\x80\\x9cthe first neuro-stimulator, which will allow patients to create their own tears.\\xe2\\x80\\x9d  \\xe2\\x80\\x9cIn the future, we\\xe2\\x80\\x99re going to see a lot more awareness as more and more innovation comes to the market,\\xe2\\x80\\x9d Cukier said. \\xe2\\x80\\x9cAnd also as clinicians more proactively engage with patients because they have more treatment options.\\xe2\\x80\\x9d  - read Allergan's news   Related Articles: Shire snags eye-drop 'addicted' Jennifer Aniston as new dry eye spokeswoman Shire targets Allergan's dry-eye market share by pricing Xiidra at $5K per year--right on par with Restasis The 'i's have it in new ad campaign for Shire\\xe2\\x80\\x99s dry eye treatment Xiidra Shire's new dry-eye approval means it's time for an Allergan showdown Allergan files with FDA for dry eye device acquired in Oculeve purchase      Read more on   dry eye , celebrity spokespeople , Allergan                                           Popular Content   Pfizer puts hemophilia spin on ultrapopular Minecraft to educate young patients Sep 06, 2017  Takeda, Johnson & Johnson and more join Clara Health's Boston-based patient empowerment push Sep 06, 2017  Empathy at work: GlaxoSmithKline extends Excedrin Migraine campaign to include sufferers on the job Sep 04, 2017  Roche nets new Actemra nod to treat deadly CAR-T response Sep 01, 2017  What's the world's best pharma market? To Allergan's CEO, that one's easy Aug 07, 2017     About the Author     Beth Snyder Bulik   beth.bulik@comcast.net                                   \\xe2\\x80\\x8b   Home  Subscribe  Manage Newsletter Subscriptions  Advertise  RSS  Privacy  About Us  Contact    \\xc2\\xa9 2017 Questex LLC. All rights reserved.  275 Grove Street, Suite 2-130 Newton, MA 02466  Reproduction in whole or part is prohibited.                        \"\n"
     ]
    }
   ],
   "source": [
    "for text in new_train['text'][:5]:\n",
    "    print(\"\\n\\n\",text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "stop_words = set(stopwords.words('english')) \n",
    "\n",
    "def text_cleaner(text):\n",
    "    #converting to lowercase\n",
    "    newString = text.lower()\n",
    "    #removing links\n",
    "    newString = re.sub(r'(https|http)?:\\/\\/(\\w|\\.|\\/|\\?|\\=|\\&|\\%)*\\b', '', newString) \n",
    "    #removing text inside ()\n",
    "    newString = re.sub(r'\\([^)]*\\)', '', newString)\n",
    "    #removing text inside []\n",
    "    newString = re.sub(r'\\{[^)]*\\}', '', newString)\n",
    "    #fetching alphabetic characters\n",
    "    newString = re.sub(\"[^a-zA-Z]\", \" \", newString)\n",
    "    #removing stop words\n",
    "    tokens = [w for w in newString.split() if not w in stop_words] \n",
    "    long_words=[]\n",
    "    for i in tokens:\n",
    "        #removing short words\n",
    "        if len(i)>=4:                                                 \n",
    "            long_words.append(i)   \n",
    "    return (\" \".join(long_words)).strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Before cleaning:\n",
      " b'    Skip to main content                                    Twitter  LinkedIn      Search           Top Menu    DDF 2017    FierceBiotech    Jobs    Resources    Events    Subscribe                  Main navigation    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory        Main navigation - Mobile    Pharma    M&A    Regulatory    Financials    Corporate    Legal      Manufacturing    M&A    Outsourcing    Regulatory    Supply Chain    Partnering    Drug Safety      Marketing    Regulatory    DTC Advertising    Digital and Social Media    Data and Analytics    Launches      Pharma Asia    M&A    R&D    Regulatory    Sales and Marketing    Financials    Manufacturing      Animal Health    R&D    M&A    Regulatory    Veterinarian    Financials    Vaccines      Drug Delivery    R&D    Regulatory    Partnering      Vaccines    Deals    Infectious Diseases    R&D    Regulatory                    Pharma          Another exec departs troubled Endo--and this time, it\\'s for another drugmaker         by Carly Helfand | Oct 21, 2016 7:05am                        Endo\\xe2\\x80\\x99s ( $ENDP ) CEO exodus is continuing. Its CFO is following its CEO out the door--to work for another drugmaker, no less.  Thursday, the Dublin company announced that financial chief, Suketu Upadhyay, would be hitting the road to \\xe2\\x80\\x9cassume a senior-level finance position at a global biopharmaceutical company.\\xe2\\x80\\x9d Blaise Coleman, Endo\\'s SVP of Global Finance Operations, will step up in his stead while Endo searches for a permanent replacement.  It\\xe2\\x80\\x99s been a rocky financial year for Endo, which--much like Valeant ( $VRX ), a company whose footsteps it\\xe2\\x80\\x99s seemingly been following in for years--slashed its Q2 guidance earlier this year,\\xc2\\xa0and the 40% share-price decline that ensued locked up the stock\\xe2\\x80\\x99s second-worse daily performance ever. It also cut 740 jobs.\\xc2\\xa0The company blamed new rivals on the market, greater-than-expected generics price erosion, regulatory delays and more for a revised revenue forecast that hit well below analyst expectations.  But new Endo skipper Paul Campanelli--the former Par chief who relieved Endo\\xe2\\x80\\x99s Rajiv De Silva late last month--was quick to point out that the company recently reaffirmed its third-quarter and full-year predictions, an attempt to reassure investors that more bad news wasn\\xe2\\x80\\x99t on the way.  What may be on the way for the troubled drugmaker, though? Divestments. Late in June, Reuters reported that Endo--like Valeant--was looking for asset sales that could help pay down its acquisition-fueled debt mountain.\\xc2\\xa0 And Thursday, Campanelli noted that the specialty pharma would \\xe2\\x80\\x9ccomplete a product-by-product assessment of our portfolio and further sharpen Endo\\'s strategy and operational focus.\"  And analysts are already talking up potential takers. Earlier this week, RBC Capital Markets\\xe2\\x80\\x99 Randall Stanicky wrote in a note to investors that Endo\\xe2\\x80\\x99s pain business could make a good buy for California\\xe2\\x80\\x99s Depomed ( $DEPO ), which may scout\\xc2\\xa0for M&A now that it\\xe2\\x80\\x99s settled a proxy dispute with activist investor Starboard Value.  - read Endo\\'s release  Special Report:  The most influential people in biopharma today - 2014 - J. Michael Pearson - Valeant  Related Articles: Depomed strikes unexpected deal with activist Starboard, adding J&J, Abbott vets to board It\\'s out with the old CEO, in with the new as Endo\\'s Campanelli takes De Silva\\'s seat Endo keeps up its Valeant act with asset-sale talks Endo\\'s Valeant-esque guidance-slashing decimates shares Valeant investors, shocked by lightweight guidance, aren\\'t buying CEO Pearson\\'s recovery plans Endo scoops up Par Pharma for $8B to gain ground in injectables Is Endo on the verge of a Valeant-type acquisition binge?    Read more on   Endo                                           Popular Content   Lilly to cut 3,500 jobs, take a $1.2B hit as it aims for $500M in savings Sep 07, 2017  After Keytruda deaths, FDA hits pause on Bristol-Myers Squibb\\'s Opdivo myeloma trials Sep 07, 2017  Survival win has Bristol-Myers\\' Opdivo-Yervoy combo looking better as first-line kidney cancer treatment Sep 07, 2017  Novo to pay nearly $60M to settle Victoza marketing suits with DOJ, whistleblowers Sep 06, 2017  Senator\\xe2\\x80\\x99s report documents deceit by former employees of embattled Insys Sep 07, 2017     About the Author        Carly Helfand  Senior Editor  chelfand@fiercemarkets.com                                   \\xe2\\x80\\x8b   Home  Subscribe  Manage Newsletter Subscriptions  Advertise  RSS  Privacy  About Us  Contact    \\xc2\\xa9 2017 Questex LLC. All rights reserved.  275 Grove Street, Suite 2-130 Newton, MA 02466  Reproduction in whole or part is prohibited.                        '\n",
      "After cleaning:\n",
      " skip main content twitter linkedin search menu fiercebiotech jobs resources events subscribe main navigation pharma regulatory financials corporate legal manufacturing outsourcing regulatory supply chain partnering drug safety marketing regulatory advertising digital social media data analytics launches pharma asia regulatory sales marketing financials manufacturing animal health regulatory veterinarian financials vaccines drug delivery regulatory partnering vaccines deals infectious diseases regulatory main navigation mobile pharma regulatory financials corporate legal manufacturing outsourcing regulatory supply chain partnering drug safety marketing regulatory advertising digital social media data analytics launches pharma asia regulatory sales marketing financials manufacturing animal health regulatory veterinarian financials vaccines drug delivery regulatory partnering vaccines deals infectious diseases regulatory pharma another exec departs troubled endo time another drugmaker carly helfand endo exodus continuing following door work another drugmaker less thursday dublin company announced financial chief suketu upadhyay would hitting road cassume senior level finance position global biopharmaceutical company blaise coleman endo global finance operations step stead endo searches permanent replacement rocky financial year endo much like valeant company whose footsteps seemingly following years slashed guidance earlier year share price decline ensued locked stock second worse daily performance ever also jobs company blamed rivals market greater expected generics price erosion regulatory delays revised revenue forecast well analyst expectations endo skipper paul campanelli former chief relieved endo rajiv silva late last month quick point company recently reaffirmed third quarter full year predictions attempt reassure investors news troubled drugmaker though divestments late june reuters reported endo like valeant looking asset sales could help acquisition fueled debt mountain thursday campanelli noted specialty pharma would ccomplete product product assessment portfolio sharpen endo strategy operational focus analysts already talking potential takers earlier week capital markets randall stanicky wrote note investors endo pain business could make good california depomed scout settled proxy dispute activist investor starboard value read endo release special report influential people biopharma today michael pearson valeant related articles depomed strikes unexpected deal activist starboard adding abbott vets board endo campanelli takes silva seat endo keeps valeant asset sale talks endo valeant esque guidance slashing decimates shares valeant investors shocked lightweight guidance buying pearson recovery plans endo scoops pharma gain ground injectables endo verge valeant type acquisition binge read endo popular content lilly jobs take aims savings keytruda deaths hits pause bristol myers squibb opdivo myeloma trials survival bristol myers opdivo yervoy combo looking better first line kidney cancer treatment novo nearly settle victoza marketing suits whistleblowers senator report documents deceit former employees embattled insys author carly helfand senior editor chelfand fiercemarkets home subscribe manage newsletter subscriptions advertise privacy contact questex rights reserved grove street suite newton reproduction whole part prohibited\n"
     ]
    }
   ],
   "source": [
    "text1 = new_train['text'][2]\n",
    "clean_text1 = text_cleaner(text1)\n",
    "print(\"Before cleaning:\\n\",text1)\n",
    "print(\"After cleaning:\\n\",clean_text1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "cleaned_text=[]\n",
    "for i in new_train['text']:\n",
    "    cleaned_text.append(text_cleaner(i))    "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2. Label Encoding\n",
    "Let us convert the output label to integer using label encoder"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0           news\n",
       "1           news\n",
       "2           news\n",
       "3           news\n",
       "4           news\n",
       "5           news\n",
       "6           news\n",
       "7           news\n",
       "8           news\n",
       "9           news\n",
       "10          news\n",
       "11          news\n",
       "12          news\n",
       "13          news\n",
       "14          news\n",
       "15          news\n",
       "16          news\n",
       "17          news\n",
       "18          news\n",
       "19          news\n",
       "20          news\n",
       "21          news\n",
       "22          news\n",
       "23          news\n",
       "24          news\n",
       "25          news\n",
       "26          news\n",
       "27          news\n",
       "28          news\n",
       "29          news\n",
       "          ...   \n",
       "53417    profile\n",
       "53418    profile\n",
       "53419    profile\n",
       "53420    profile\n",
       "53421    profile\n",
       "53422    profile\n",
       "53423    profile\n",
       "53424    profile\n",
       "53425    profile\n",
       "53426    profile\n",
       "53427    profile\n",
       "53428    profile\n",
       "53429    profile\n",
       "53430    profile\n",
       "53431    profile\n",
       "53432    profile\n",
       "53433    profile\n",
       "53434    profile\n",
       "53435    profile\n",
       "53436    profile\n",
       "53437    profile\n",
       "53438    profile\n",
       "53439    profile\n",
       "53440    profile\n",
       "53441    profile\n",
       "53442    profile\n",
       "53443    profile\n",
       "53444    profile\n",
       "53445    profile\n",
       "53446    profile\n",
       "Name: Tag, Length: 53447, dtype: object"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "new_train['Tag']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.preprocessing import LabelEncoder\n",
    "le = LabelEncoder()\n",
    "y=le.fit_transform(new_train['Tag'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([4, 4, 4, ..., 6, 6, 6])"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "y"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3. Validation Split\n",
    "Let us split the dataset in the ratio of 7:3 and evaluate the performance of model on 30% of the data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.model_selection import train_test_split\n",
    "x_tr,x_val,y_tr,y_val=train_test_split(cleaned_text,y,test_size=0.3,random_state=0,shuffle=True) "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 4. Padding\n",
    "\n",
    "**Distribution of sequences**\n",
    "\n",
    "Here, we create the distribution for the length of the sequences and fix the maximum length of sequence which is required for building the model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x7ffa3bacbe10>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "text_word_count = []\n",
    "\n",
    "#populate the lists with sentence lengths\n",
    "for i in cleaned_text:\n",
    "      text_word_count.append(len(i.split()))\n",
    "\n",
    "length_df = pd.DataFrame({'text':text_word_count})\n",
    "\n",
    "length_df.hist(bins = 100, range=(0,10000))\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "From the above histogram, we observe that most of the sequences fall under the length of 500. So, let us fix maximum length of sequence to 500."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "max_len=500"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Preparing Tokenizer**\n",
    "\n",
    "1.Here, we create the vocabulary ( refers to all the unique words in the entire dataset) and assign index to every unique word.\n",
    "\n",
    "2.Using the word index, we convert the word sequence to integer sequence.\n",
    "\n",
    "3.Append zero upto the maximum length of sequence so that all the sequences are of same length"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Using TensorFlow backend.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vocabulary size: 467704\n"
     ]
    }
   ],
   "source": [
    "from keras.preprocessing.text import Tokenizer \n",
    "from keras.preprocessing.sequence import pad_sequences\n",
    "\n",
    "tokenizer = Tokenizer()\n",
    "#creating index for a wor\n",
    "tokenizer.fit_on_texts(list(x_tr))\n",
    "\n",
    "#converting word seq to integer seq\n",
    "x_tr    =   tokenizer.texts_to_sequences(x_tr) \n",
    "x_val   =   tokenizer.texts_to_sequences(x_val)\n",
    "\n",
    "#padding up with zero \n",
    "x_tr    =   pad_sequences(x_tr,  maxlen=max_len, padding='post')\n",
    "x_val   =   pad_sequences(x_val, maxlen=max_len, padding='post')\n",
    "\n",
    "vocabulary   =  len(tokenizer.word_index) +1\n",
    "print(\"Vocabulary size:\",vocabulary)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([   364,    178,     91,    959,   2157,    362,     35,   1506,\n",
       "          419,   1398,   1561,    419,    319,    319,   2587,    319,\n",
       "         3589,   1852,    357,     77,    279,     77,    141,    123,\n",
       "          163,    371,    279,     48,     71,     10,    809,    321,\n",
       "          447,     33,    212,     33,   7673,   5287,   2394,    140,\n",
       "           70,    380,    350,     19,     10,    312,     99,    212,\n",
       "         2779,   1987,   1225,     91,    268,    357,    160,    323,\n",
       "         7047,     44,   8007,    166,   2979,     16,    106,     16,\n",
       "          226,     91,      7,    565,     59,   1529,     48,      7,\n",
       "          565,     59,     16,    180,     16,    265,      7,    232,\n",
       "            7,    202,    415,    163,   1831,    153,    156,      7,\n",
       "           62,    162,    111,    826,   5202,     70,   3961,    153,\n",
       "         2642,    530,      9,   2642,   1236,      9,    709,    273,\n",
       "           93,    281,    843,   3025,    843,    622,   4311,     14,\n",
       "         3896,   3896,     16,     77,     71,   3307,  41236,   3307,\n",
       "        41236,     16,     77,     71,  22376,  30006,  22376,  30006,\n",
       "           16,     77,     71,   7288,  16768,   7288,  16768,     16,\n",
       "           77,     71, 210648,   9351, 210648,   9351,     16,     77,\n",
       "           71,   6438,  27340,   6438,  27340,     16,     77,     71,\n",
       "         2477,   2705,   8355,   6424,   3396,  12032,    709,    273,\n",
       "           93,    281,    843,   3025,    843,    622,   4311,     14,\n",
       "           59,     62,    102,    701,     22,     57,     77,      9,\n",
       "           62,    102,    162,    362,  11202,    689,   1961,   1852,\n",
       "          628,      9,     62,    102,   5541,    843,   3025,   3409,\n",
       "          253,  12835,    910,  33417,    843,   1120,    916,    965,\n",
       "         1260,     67,    200,    843,    622,    160,    265,     58,\n",
       "         1866,    105,  10686,    965,    843,   3025,     70,      7,\n",
       "          162,   1317,    826,    362,   1781,    295,   1561,    419,\n",
       "          319,    630,    295,   1961,     70,      7,    139,    535,\n",
       "          140,     70,   3589,     70,    123,   4988,     60,   1184,\n",
       "          295,    101,   3589,     70,    357,    565,   1961,   1852,\n",
       "         1878,     70,     77,     33,   1308,     70,    246,   5541,\n",
       "           70,   1501,    145,   3741,     70,      7,   5541,    246,\n",
       "         5541,     70,   1501,      7,    322,     35,      7,   1482,\n",
       "          371,   1728,    438,    630,    438,   1463,   1079,   4707,\n",
       "          542,    809,    417,   1225,      7,     57,   3565,      7,\n",
       "           57,    509,     57,     77,   4094,     57,     77,    265,\n",
       "            7,    232,      7,    202,    415,    163,   1831,    153,\n",
       "          182,   3741,    193,    377,    115,     49,    106,    124,\n",
       "          384,     87,     19,    894,     91,     40,   1311,      2,\n",
       "          289,   5501,     40,   4451,   3823,   5074,     33,    105,\n",
       "          888,    121,    299,    166,   3147,    345,   2215,    139,\n",
       "         1512,    987,    562,   4736,    741,    843,   3025,    843,\n",
       "          622,   4311,     14,   3896,   2084,   4128,   2502,   6367,\n",
       "        24617,    788,   5486,    392,  10947,     91,  22363,   3312,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0,      0,      0,      0,      0,\n",
       "            0,      0,      0,      0], dtype=int32)"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#sequence encoding and padding\n",
    "x_tr[7128]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'cancer': 1,\n",
       " 'health': 2,\n",
       " 'research': 3,\n",
       " 'patients': 4,\n",
       " 'google': 5,\n",
       " 'pubmed': 6,\n",
       " 'article': 7,\n",
       " 'cells': 8,\n",
       " 'view': 9,\n",
       " 'information': 10,\n",
       " 'scholar': 11,\n",
       " 'clinical': 12,\n",
       " 'cell': 13,\n",
       " 'study': 14,\n",
       " 'care': 15,\n",
       " 'search': 16,\n",
       " 'conference': 17,\n",
       " 'medical': 18,\n",
       " 'contact': 19,\n",
       " 'treatment': 20,\n",
       " 'patient': 21,\n",
       " 'data': 22,\n",
       " 'medicine': 23,\n",
       " 'news': 24,\n",
       " 'university': 25,\n",
       " 'disease': 26,\n",
       " 'also': 27,\n",
       " 'science': 28,\n",
       " 'international': 29,\n",
       " 'results': 30,\n",
       " 'development': 31,\n",
       " 'home': 32,\n",
       " 'journal': 33,\n",
       " 'time': 34,\n",
       " 'email': 35,\n",
       " 'using': 36,\n",
       " 'management': 37,\n",
       " 'group': 38,\n",
       " 'share': 39,\n",
       " 'site': 40,\n",
       " 'expression': 41,\n",
       " 'center': 42,\n",
       " 'services': 43,\n",
       " 'find': 44,\n",
       " 'analysis': 45,\n",
       " 'human': 46,\n",
       " 'products': 47,\n",
       " 'authors': 48,\n",
       " 'policy': 49,\n",
       " 'hospital': 50,\n",
       " 'global': 51,\n",
       " 'overview': 52,\n",
       " 'central': 53,\n",
       " 'free': 54,\n",
       " 'first': 55,\n",
       " 'tumor': 56,\n",
       " 'related': 57,\n",
       " 'studies': 58,\n",
       " 'abstract': 59,\n",
       " 'society': 60,\n",
       " 'people': 61,\n",
       " 'full': 62,\n",
       " 'support': 63,\n",
       " 'used': 64,\n",
       " 'media': 65,\n",
       " 'high': 66,\n",
       " 'risk': 67,\n",
       " 'life': 68,\n",
       " 'healthcare': 69,\n",
       " 'access': 70,\n",
       " 'author': 71,\n",
       " 'protein': 72,\n",
       " 'conferences': 73,\n",
       " 'program': 74,\n",
       " 'world': 75,\n",
       " 'based': 76,\n",
       " 'articles': 77,\n",
       " 'control': 78,\n",
       " 'events': 79,\n",
       " 'type': 80,\n",
       " 'crossref': 81,\n",
       " 'therapy': 82,\n",
       " 'years': 83,\n",
       " 'drug': 84,\n",
       " 'united': 85,\n",
       " 'resources': 86,\n",
       " 'help': 87,\n",
       " 'well': 88,\n",
       " 'report': 89,\n",
       " 'surgery': 90,\n",
       " 'content': 91,\n",
       " 'education': 92,\n",
       " 'year': 93,\n",
       " 'open': 94,\n",
       " 'gene': 95,\n",
       " 'business': 96,\n",
       " 'call': 97,\n",
       " 'trials': 98,\n",
       " 'board': 99,\n",
       " 'work': 100,\n",
       " 'number': 101,\n",
       " 'text': 102,\n",
       " 'blood': 103,\n",
       " 'breast': 104,\n",
       " 'association': 105,\n",
       " 'terms': 106,\n",
       " 'primary': 107,\n",
       " 'bayer': 108,\n",
       " 'system': 109,\n",
       " 'like': 110,\n",
       " 'review': 111,\n",
       " 'diseases': 112,\n",
       " 'associated': 113,\n",
       " 'children': 114,\n",
       " 'privacy': 115,\n",
       " 'jobs': 116,\n",
       " 'trial': 117,\n",
       " 'follow': 118,\n",
       " 'openurl': 119,\n",
       " 'general': 120,\n",
       " 'quality': 121,\n",
       " 'women': 122,\n",
       " 'current': 123,\n",
       " 'conditions': 124,\n",
       " 'activity': 125,\n",
       " 'american': 126,\n",
       " 'pain': 127,\n",
       " 'company': 128,\n",
       " 'public': 129,\n",
       " 'heart': 130,\n",
       " 'twitter': 131,\n",
       " 'date': 132,\n",
       " 'family': 133,\n",
       " 'pregnancy': 134,\n",
       " 'food': 135,\n",
       " 'back': 136,\n",
       " 'national': 137,\n",
       " 'safety': 138,\n",
       " 'download': 139,\n",
       " 'online': 140,\n",
       " 'press': 141,\n",
       " 'levels': 142,\n",
       " 'including': 143,\n",
       " 'community': 144,\n",
       " 'published': 145,\n",
       " 'institute': 146,\n",
       " 'department': 147,\n",
       " 'growth': 148,\n",
       " 'different': 149,\n",
       " 'annual': 150,\n",
       " 'states': 151,\n",
       " 'effects': 152,\n",
       " 'page': 153,\n",
       " 'specific': 154,\n",
       " 'oncology': 155,\n",
       " 'read': 156,\n",
       " 'name': 157,\n",
       " 'website': 158,\n",
       " 'post': 159,\n",
       " 'diabetes': 160,\n",
       " 'september': 161,\n",
       " 'please': 162,\n",
       " 'issue': 163,\n",
       " 'technology': 164,\n",
       " 'facebook': 165,\n",
       " 'product': 166,\n",
       " 'found': 167,\n",
       " 'would': 168,\n",
       " 'reports': 169,\n",
       " 'investor': 170,\n",
       " 'could': 171,\n",
       " 'molecular': 172,\n",
       " 'social': 173,\n",
       " 'available': 174,\n",
       " 'however': 175,\n",
       " 'school': 176,\n",
       " 'financial': 177,\n",
       " 'main': 178,\n",
       " 'menu': 179,\n",
       " 'advanced': 180,\n",
       " 'scientific': 181,\n",
       " 'copyright': 182,\n",
       " 'response': 183,\n",
       " 'corporate': 184,\n",
       " 'lung': 185,\n",
       " 'effect': 186,\n",
       " 'doctor': 187,\n",
       " 'history': 188,\n",
       " 'many': 189,\n",
       " 'week': 190,\n",
       " 'role': 191,\n",
       " 'guidelines': 192,\n",
       " 'rights': 193,\n",
       " 'make': 194,\n",
       " 'methods': 195,\n",
       " 'service': 196,\n",
       " 'best': 197,\n",
       " 'careers': 198,\n",
       " 'genes': 199,\n",
       " 'factor': 200,\n",
       " 'member': 201,\n",
       " 'october': 202,\n",
       " 'case': 203,\n",
       " 'practice': 204,\n",
       " 'increased': 205,\n",
       " 'medline': 206,\n",
       " 'june': 207,\n",
       " 'weeks': 208,\n",
       " 'sciences': 209,\n",
       " 'congress': 210,\n",
       " 'part': 211,\n",
       " 'info': 212,\n",
       " 'figure': 213,\n",
       " 'november': 214,\n",
       " 'three': 215,\n",
       " 'evidence': 216,\n",
       " 'level': 217,\n",
       " 'august': 218,\n",
       " 'learn': 219,\n",
       " 'important': 220,\n",
       " 'following': 221,\n",
       " 'significant': 222,\n",
       " 'journals': 223,\n",
       " 'meeting': 224,\n",
       " 'march': 225,\n",
       " 'within': 226,\n",
       " 'brain': 227,\n",
       " 'section': 228,\n",
       " 'diagnosis': 229,\n",
       " 'positive': 230,\n",
       " 'innovation': 231,\n",
       " 'next': 232,\n",
       " 'factors': 233,\n",
       " 'long': 234,\n",
       " 'table': 235,\n",
       " 'without': 236,\n",
       " 'tissue': 237,\n",
       " 'july': 238,\n",
       " 'anti': 239,\n",
       " 'compared': 240,\n",
       " 'test': 241,\n",
       " 'need': 242,\n",
       " 'impact': 243,\n",
       " 'experience': 244,\n",
       " 'months': 245,\n",
       " 'visit': 246,\n",
       " 'reported': 247,\n",
       " 'biology': 248,\n",
       " 'nutrition': 249,\n",
       " 'induced': 250,\n",
       " 'tumors': 251,\n",
       " 'know': 252,\n",
       " 'early': 253,\n",
       " 'small': 254,\n",
       " 'december': 255,\n",
       " 'training': 256,\n",
       " 'areas': 257,\n",
       " 'committee': 258,\n",
       " 'engineering': 259,\n",
       " 'process': 260,\n",
       " 'working': 261,\n",
       " 'normal': 262,\n",
       " 'baby': 263,\n",
       " 'address': 264,\n",
       " 'previous': 265,\n",
       " 'chronic': 266,\n",
       " 'south': 267,\n",
       " 'alerts': 268,\n",
       " 'total': 269,\n",
       " 'april': 270,\n",
       " 'days': 271,\n",
       " 'body': 272,\n",
       " 'proteins': 273,\n",
       " 'cases': 274,\n",
       " 'phase': 275,\n",
       " 'mice': 276,\n",
       " 'among': 277,\n",
       " 'last': 278,\n",
       " 'issues': 279,\n",
       " 'treated': 280,\n",
       " 'change': 281,\n",
       " 'blog': 282,\n",
       " 'potential': 283,\n",
       " 'groups': 284,\n",
       " 'sign': 285,\n",
       " 'form': 286,\n",
       " 'model': 287,\n",
       " 'programs': 288,\n",
       " 'professionals': 289,\n",
       " 'market': 290,\n",
       " 'policies': 291,\n",
       " 'materials': 292,\n",
       " 'drugs': 293,\n",
       " 'team': 294,\n",
       " 'account': 295,\n",
       " 'china': 296,\n",
       " 'function': 297,\n",
       " 'changes': 298,\n",
       " 'value': 299,\n",
       " 'meet': 300,\n",
       " 'germany': 301,\n",
       " 'january': 302,\n",
       " 'recent': 303,\n",
       " 'state': 304,\n",
       " 'provide': 305,\n",
       " 'good': 306,\n",
       " 'receptor': 307,\n",
       " 'pregnant': 308,\n",
       " 'nursing': 309,\n",
       " 'close': 310,\n",
       " 'reply': 311,\n",
       " 'editorial': 312,\n",
       " 'shown': 313,\n",
       " 'outcome': 314,\n",
       " 'future': 315,\n",
       " 'systems': 316,\n",
       " 'details': 317,\n",
       " 'links': 318,\n",
       " 'register': 319,\n",
       " 'publications': 320,\n",
       " 'submit': 321,\n",
       " 'tools': 322,\n",
       " 'canada': 323,\n",
       " 'european': 324,\n",
       " 'multiple': 325,\n",
       " 'japan': 326,\n",
       " 'survival': 327,\n",
       " 'original': 328,\n",
       " 'provided': 329,\n",
       " 'papers': 330,\n",
       " 'query': 331,\n",
       " 'amgen': 332,\n",
       " 'values': 333,\n",
       " 'healthy': 334,\n",
       " 'imaging': 335,\n",
       " 'better': 336,\n",
       " 'status': 337,\n",
       " 'network': 338,\n",
       " 'loss': 339,\n",
       " 'performed': 340,\n",
       " 'references': 341,\n",
       " 'present': 342,\n",
       " 'disorders': 343,\n",
       " 'rate': 344,\n",
       " 'made': 345,\n",
       " 'australia': 346,\n",
       " 'increase': 347,\n",
       " 'members': 348,\n",
       " 'cardiology': 349,\n",
       " 'opportunities': 350,\n",
       " 'dose': 351,\n",
       " 'higher': 352,\n",
       " 'locations': 353,\n",
       " 'infection': 354,\n",
       " 'posts': 355,\n",
       " 'file': 356,\n",
       " 'subscribe': 357,\n",
       " 'take': 358,\n",
       " 'samples': 359,\n",
       " 'carcinoma': 360,\n",
       " 'common': 361,\n",
       " 'login': 362,\n",
       " 'activation': 363,\n",
       " 'skip': 364,\n",
       " 'biomed': 365,\n",
       " 'responsibility': 366,\n",
       " 'statement': 367,\n",
       " 'show': 368,\n",
       " 'liver': 369,\n",
       " 'february': 370,\n",
       " 'list': 371,\n",
       " 'target': 372,\n",
       " 'library': 373,\n",
       " 'stage': 374,\n",
       " 'additional': 375,\n",
       " 'single': 376,\n",
       " 'reserved': 377,\n",
       " 'forum': 378,\n",
       " 'area': 379,\n",
       " 'career': 380,\n",
       " 'college': 381,\n",
       " 'population': 382,\n",
       " 'office': 383,\n",
       " 'cookies': 384,\n",
       " 'design': 385,\n",
       " 'pharmaceutical': 386,\n",
       " 'comments': 387,\n",
       " 'investors': 388,\n",
       " 'improve': 389,\n",
       " 'foundation': 390,\n",
       " 'similar': 391,\n",
       " 'size': 392,\n",
       " 'archive': 393,\n",
       " 'acute': 394,\n",
       " 'sample': 395,\n",
       " 'prevention': 396,\n",
       " 'intervention': 397,\n",
       " 'observed': 398,\n",
       " 'cardiovascular': 399,\n",
       " 'even': 400,\n",
       " 'since': 401,\n",
       " 'today': 402,\n",
       " 'benefits': 403,\n",
       " 'addition': 404,\n",
       " 'biol': 405,\n",
       " 'latest': 406,\n",
       " 'profile': 407,\n",
       " 'local': 408,\n",
       " 'showed': 409,\n",
       " 'europe': 410,\n",
       " 'secondary': 411,\n",
       " 'event': 412,\n",
       " 'signaling': 413,\n",
       " 'significantly': 414,\n",
       " 'volume': 415,\n",
       " 'include': 416,\n",
       " 'order': 417,\n",
       " 'term': 418,\n",
       " 'password': 419,\n",
       " 'award': 420,\n",
       " 'organization': 421,\n",
       " 'strategy': 422,\n",
       " 'fertility': 423,\n",
       " 'line': 424,\n",
       " 'oral': 425,\n",
       " 'child': 426,\n",
       " 'manager': 427,\n",
       " 'medicines': 428,\n",
       " 'second': 429,\n",
       " 'plus': 430,\n",
       " 'several': 431,\n",
       " 'america': 432,\n",
       " 'subject': 433,\n",
       " 'faculty': 434,\n",
       " 'reference': 435,\n",
       " 'english': 436,\n",
       " 'immune': 437,\n",
       " 'citation': 438,\n",
       " 'pediatric': 439,\n",
       " 'skin': 440,\n",
       " 'screening': 441,\n",
       " 'right': 442,\n",
       " 'italy': 443,\n",
       " 'clin': 444,\n",
       " 'questions': 445,\n",
       " 'vaccines': 446,\n",
       " 'manuscript': 447,\n",
       " 'genetic': 448,\n",
       " 'pharma': 449,\n",
       " 'million': 450,\n",
       " 'possible': 451,\n",
       " 'approach': 452,\n",
       " 'active': 453,\n",
       " 'industry': 454,\n",
       " 'criteria': 455,\n",
       " 'types': 456,\n",
       " 'past': 457,\n",
       " 'join': 458,\n",
       " 'spain': 459,\n",
       " 'performance': 460,\n",
       " 'culture': 461,\n",
       " 'known': 462,\n",
       " 'physical': 463,\n",
       " 'production': 464,\n",
       " 'binding': 465,\n",
       " 'identified': 466,\n",
       " 'meetings': 467,\n",
       " 'received': 468,\n",
       " 'weight': 469,\n",
       " 'less': 470,\n",
       " 'required': 471,\n",
       " 'application': 472,\n",
       " 'interest': 473,\n",
       " 'symptoms': 474,\n",
       " 'testing': 475,\n",
       " 'discussion': 476,\n",
       " 'clinic': 477,\n",
       " 'sites': 478,\n",
       " 'much': 479,\n",
       " 'major': 480,\n",
       " 'outcomes': 481,\n",
       " 'want': 482,\n",
       " 'india': 483,\n",
       " 'bone': 484,\n",
       " 'series': 485,\n",
       " 'select': 486,\n",
       " 'every': 487,\n",
       " 'leadership': 488,\n",
       " 'solutions': 489,\n",
       " 'mail': 490,\n",
       " 'pharmaceuticals': 491,\n",
       " 'asia': 492,\n",
       " 'large': 493,\n",
       " 'france': 494,\n",
       " 'publication': 495,\n",
       " 'cycle': 496,\n",
       " 'plan': 497,\n",
       " 'stem': 498,\n",
       " 'funding': 499,\n",
       " 'ethics': 500,\n",
       " 'although': 501,\n",
       " 'method': 502,\n",
       " 'regulation': 503,\n",
       " 'marketing': 504,\n",
       " 'focus': 505,\n",
       " 'region': 506,\n",
       " 'students': 507,\n",
       " 'releases': 508,\n",
       " 'video': 509,\n",
       " 'country': 510,\n",
       " 'acid': 511,\n",
       " 'special': 512,\n",
       " 'cancers': 513,\n",
       " 'chemotherapy': 514,\n",
       " 'whether': 515,\n",
       " 'around': 516,\n",
       " 'involved': 517,\n",
       " 'chemistry': 518,\n",
       " 'novel': 519,\n",
       " 'feedback': 520,\n",
       " 'assessment': 521,\n",
       " 'environmental': 522,\n",
       " 'nature': 523,\n",
       " 'therapeutic': 524,\n",
       " 'regulatory': 525,\n",
       " 'individual': 526,\n",
       " 'independent': 527,\n",
       " 'point': 528,\n",
       " 'north': 529,\n",
       " 'standard': 530,\n",
       " 'sales': 531,\n",
       " 'guideline': 532,\n",
       " 'physician': 533,\n",
       " 'print': 534,\n",
       " 'hours': 535,\n",
       " 'infertility': 536,\n",
       " 'pathway': 537,\n",
       " 'version': 538,\n",
       " 'release': 539,\n",
       " 'living': 540,\n",
       " 'treatments': 541,\n",
       " 'request': 542,\n",
       " 'mean': 543,\n",
       " 'across': 544,\n",
       " 'videos': 545,\n",
       " 'surgical': 546,\n",
       " 'another': 547,\n",
       " 'cardiac': 548,\n",
       " 'lower': 549,\n",
       " 'africa': 550,\n",
       " 'included': 551,\n",
       " 'countries': 552,\n",
       " 'prostate': 553,\n",
       " 'activities': 554,\n",
       " 'presence': 555,\n",
       " 'physicians': 556,\n",
       " 'obesity': 557,\n",
       " 'awards': 558,\n",
       " 'kinase': 559,\n",
       " 'linkedin': 560,\n",
       " 'side': 561,\n",
       " 'syndrome': 562,\n",
       " 'location': 563,\n",
       " 'energy': 564,\n",
       " 'title': 565,\n",
       " 'negative': 566,\n",
       " 'start': 567,\n",
       " 'might': 568,\n",
       " 'complex': 569,\n",
       " 'knowledge': 570,\n",
       " 'lines': 571,\n",
       " 'cause': 572,\n",
       " 'employees': 573,\n",
       " 'according': 574,\n",
       " 'dependent': 575,\n",
       " 'effective': 576,\n",
       " 'city': 577,\n",
       " 'staff': 578,\n",
       " 'immunology': 579,\n",
       " 'participants': 580,\n",
       " 'chemical': 581,\n",
       " 'virus': 582,\n",
       " 'personal': 583,\n",
       " 'either': 584,\n",
       " 'renal': 585,\n",
       " 'worldwide': 586,\n",
       " 'laboratory': 587,\n",
       " 'professional': 588,\n",
       " 'field': 589,\n",
       " 'governance': 590,\n",
       " 'result': 591,\n",
       " 'mutations': 592,\n",
       " 'various': 593,\n",
       " 'netherlands': 594,\n",
       " 'radiation': 595,\n",
       " 'period': 596,\n",
       " 'serum': 597,\n",
       " 'water': 598,\n",
       " 'said': 599,\n",
       " 'administration': 600,\n",
       " 'give': 601,\n",
       " 'link': 602,\n",
       " 'range': 603,\n",
       " 'stories': 604,\n",
       " 'receive': 605,\n",
       " 'says': 606,\n",
       " 'genome': 607,\n",
       " 'times': 608,\n",
       " 'cellular': 609,\n",
       " 'background': 610,\n",
       " 'findings': 611,\n",
       " 'month': 612,\n",
       " 'code': 613,\n",
       " 'centre': 614,\n",
       " 'functional': 615,\n",
       " 'kidney': 616,\n",
       " 'navigation': 617,\n",
       " 'london': 618,\n",
       " 'stock': 619,\n",
       " 'natural': 620,\n",
       " 'message': 621,\n",
       " 'resistance': 622,\n",
       " 'action': 623,\n",
       " 'still': 624,\n",
       " 'pathology': 625,\n",
       " 'described': 626,\n",
       " 'disorder': 627,\n",
       " 'click': 628,\n",
       " 'must': 629,\n",
       " 'create': 630,\n",
       " 'overall': 631,\n",
       " 'stress': 632,\n",
       " 'limited': 633,\n",
       " 'apoptosis': 634,\n",
       " 'death': 635,\n",
       " 'insurance': 636,\n",
       " 'complete': 637,\n",
       " 'mass': 638,\n",
       " 'therefore': 639,\n",
       " 'software': 640,\n",
       " 'reporting': 641,\n",
       " 'project': 642,\n",
       " 'critical': 643,\n",
       " 'mediated': 644,\n",
       " 'issn': 645,\n",
       " 'animal': 646,\n",
       " 'developed': 647,\n",
       " 'topics': 648,\n",
       " 'young': 649,\n",
       " 'republic': 650,\n",
       " 'four': 651,\n",
       " 'prior': 652,\n",
       " 'registration': 653,\n",
       " 'presentations': 654,\n",
       " 'condition': 655,\n",
       " 'mission': 656,\n",
       " 'partners': 657,\n",
       " 'least': 658,\n",
       " 'browse': 659,\n",
       " 'centers': 660,\n",
       " 'companies': 661,\n",
       " 'director': 662,\n",
       " 'source': 663,\n",
       " 'considered': 664,\n",
       " 'given': 665,\n",
       " 'researchers': 666,\n",
       " 'great': 667,\n",
       " 'third': 668,\n",
       " 'apply': 669,\n",
       " 'abstracts': 670,\n",
       " 'index': 671,\n",
       " 'environment': 672,\n",
       " 'leukemia': 673,\n",
       " 'rates': 674,\n",
       " 'compliance': 675,\n",
       " 'distribution': 676,\n",
       " 'live': 677,\n",
       " 'graduate': 678,\n",
       " 'legal': 679,\n",
       " 'leading': 680,\n",
       " 'head': 681,\n",
       " 'antibody': 682,\n",
       " 'discovery': 683,\n",
       " 'vascular': 684,\n",
       " 'evaluation': 685,\n",
       " 'real': 686,\n",
       " 'developing': 687,\n",
       " 'diagnostic': 688,\n",
       " 'user': 689,\n",
       " 'subjects': 690,\n",
       " 'thus': 691,\n",
       " 'develop': 692,\n",
       " 'melanoma': 693,\n",
       " 'responsible': 694,\n",
       " 'person': 695,\n",
       " 'explore': 696,\n",
       " 'difference': 697,\n",
       " 'track': 698,\n",
       " 'delivery': 699,\n",
       " 'making': 700,\n",
       " 'images': 701,\n",
       " 'nuclear': 702,\n",
       " 'statements': 703,\n",
       " 'often': 704,\n",
       " 'summary': 705,\n",
       " 'adult': 706,\n",
       " 'previously': 707,\n",
       " 'structure': 708,\n",
       " 'inflammatory': 709,\n",
       " 'image': 710,\n",
       " 'registered': 711,\n",
       " 'needs': 712,\n",
       " 'genetics': 713,\n",
       " 'appointment': 714,\n",
       " 'combination': 715,\n",
       " 'thank': 716,\n",
       " 'programme': 717,\n",
       " 'failure': 718,\n",
       " 'internal': 719,\n",
       " 'approved': 720,\n",
       " 'mechanisms': 721,\n",
       " 'think': 722,\n",
       " 'become': 723,\n",
       " 'self': 724,\n",
       " 'student': 725,\n",
       " 'advertisement': 726,\n",
       " 'biological': 727,\n",
       " 'expressed': 728,\n",
       " 'five': 729,\n",
       " 'leave': 730,\n",
       " 'likely': 731,\n",
       " 'mouse': 732,\n",
       " 'recruitment': 733,\n",
       " 'course': 734,\n",
       " 'microbiology': 735,\n",
       " 'models': 736,\n",
       " 'doctors': 737,\n",
       " 'core': 738,\n",
       " 'able': 739,\n",
       " 'inclusion': 740,\n",
       " 'progression': 741,\n",
       " 'inhibition': 742,\n",
       " 'reduced': 743,\n",
       " 'submission': 744,\n",
       " 'muscle': 745,\n",
       " 'consumer': 746,\n",
       " 'position': 747,\n",
       " 'calendar': 748,\n",
       " 'detection': 749,\n",
       " 'understanding': 750,\n",
       " 'price': 751,\n",
       " 'differences': 752,\n",
       " 'phone': 753,\n",
       " 'feel': 754,\n",
       " 'radiology': 755,\n",
       " 'looking': 756,\n",
       " 'obtained': 757,\n",
       " 'ovarian': 758,\n",
       " 'contents': 759,\n",
       " 'endnote': 760,\n",
       " 'exposure': 761,\n",
       " 'infectious': 762,\n",
       " 'colorectal': 763,\n",
       " 'diversity': 764,\n",
       " 'technologies': 765,\n",
       " 'opportunity': 766,\n",
       " 'controlled': 767,\n",
       " 'vitro': 768,\n",
       " 'responses': 769,\n",
       " 'cost': 770,\n",
       " 'singapore': 771,\n",
       " 'paper': 772,\n",
       " 'giving': 773,\n",
       " 'going': 774,\n",
       " 'short': 775,\n",
       " 'efficacy': 776,\n",
       " 'provides': 777,\n",
       " 'plant': 778,\n",
       " 'executive': 779,\n",
       " 'mental': 780,\n",
       " 'kingdom': 781,\n",
       " 'standards': 782,\n",
       " 'features': 783,\n",
       " 'proliferation': 784,\n",
       " 'korea': 785,\n",
       " 'others': 786,\n",
       " 'grants': 787,\n",
       " 'containing': 788,\n",
       " 'guide': 789,\n",
       " 'experimental': 790,\n",
       " 'pulmonary': 791,\n",
       " 'diet': 792,\n",
       " 'accepted': 793,\n",
       " 'digital': 794,\n",
       " 'tests': 795,\n",
       " 'together': 796,\n",
       " 'sleep': 797,\n",
       " 'manufacturing': 798,\n",
       " 'medium': 799,\n",
       " 'severe': 800,\n",
       " 'getting': 801,\n",
       " 'language': 802,\n",
       " 'class': 803,\n",
       " 'hypertension': 804,\n",
       " 'sequence': 805,\n",
       " 'pacific': 806,\n",
       " 'contrast': 807,\n",
       " 'pathways': 808,\n",
       " 'permissions': 809,\n",
       " 'york': 810,\n",
       " 'supply': 811,\n",
       " 'presentation': 812,\n",
       " 'place': 813,\n",
       " 'reviews': 814,\n",
       " 'adults': 815,\n",
       " 'recommendations': 816,\n",
       " 'relevant': 817,\n",
       " 'wang': 818,\n",
       " 'domain': 819,\n",
       " 'ireland': 820,\n",
       " 'emergency': 821,\n",
       " 'applications': 822,\n",
       " 'lead': 823,\n",
       " 'sustainability': 824,\n",
       " 'forward': 825,\n",
       " 'options': 826,\n",
       " 'vaccine': 827,\n",
       " 'individuals': 828,\n",
       " 'assay': 829,\n",
       " 'pediatrics': 830,\n",
       " 'agents': 831,\n",
       " 'practices': 832,\n",
       " 'birth': 833,\n",
       " 'switzerland': 834,\n",
       " 'posted': 835,\n",
       " 'transfer': 836,\n",
       " 'dental': 837,\n",
       " 'demonstrated': 838,\n",
       " 'division': 839,\n",
       " 'newsletter': 840,\n",
       " 'mortality': 841,\n",
       " 'daily': 842,\n",
       " 'insulin': 843,\n",
       " 'chem': 844,\n",
       " 'magazine': 845,\n",
       " 'randomized': 846,\n",
       " 'little': 847,\n",
       " 'exercise': 848,\n",
       " 'respectively': 849,\n",
       " 'survey': 850,\n",
       " 'applied': 851,\n",
       " 'pressure': 852,\n",
       " 'grant': 853,\n",
       " 'always': 854,\n",
       " 'boston': 855,\n",
       " 'east': 856,\n",
       " 'otherwise': 857,\n",
       " 'measured': 858,\n",
       " 'oncol': 859,\n",
       " 'california': 860,\n",
       " 'category': 861,\n",
       " 'commitment': 862,\n",
       " 'sports': 863,\n",
       " 'president': 864,\n",
       " 'things': 865,\n",
       " 'material': 866,\n",
       " 'degree': 867,\n",
       " 'comment': 868,\n",
       " 'really': 869,\n",
       " 'final': 870,\n",
       " 'license': 871,\n",
       " 'dermatology': 872,\n",
       " 'mendeley': 873,\n",
       " 'metabolism': 874,\n",
       " 'partnerships': 875,\n",
       " 'notice': 876,\n",
       " 'fund': 877,\n",
       " 'determine': 878,\n",
       " 'identify': 879,\n",
       " 'recently': 880,\n",
       " 'hope': 881,\n",
       " 'ability': 882,\n",
       " 'metrics': 883,\n",
       " 'poster': 884,\n",
       " 'brazil': 885,\n",
       " 'neurology': 886,\n",
       " 'therapies': 887,\n",
       " 'publisher': 888,\n",
       " 'transcription': 889,\n",
       " 'inhibitor': 890,\n",
       " 'injury': 891,\n",
       " 'lymphoma': 892,\n",
       " 'refworks': 893,\n",
       " 'accessibility': 894,\n",
       " 'relations': 895,\n",
       " 'youtube': 896,\n",
       " 'database': 897,\n",
       " 'learning': 898,\n",
       " 'interests': 899,\n",
       " 'vivo': 900,\n",
       " 'injection': 901,\n",
       " 'diagnosed': 902,\n",
       " 'determined': 903,\n",
       " 'provider': 904,\n",
       " 'mrna': 905,\n",
       " 'plasma': 906,\n",
       " 'peer': 907,\n",
       " 'male': 908,\n",
       " 'derived': 909,\n",
       " 'mechanism': 910,\n",
       " 'cross': 911,\n",
       " 'problems': 912,\n",
       " 'highly': 913,\n",
       " 'story': 914,\n",
       " 'david': 915,\n",
       " 'grade': 916,\n",
       " 'commercial': 917,\n",
       " 'strong': 918,\n",
       " 'mexico': 919,\n",
       " 'treat': 920,\n",
       " 'infections': 921,\n",
       " 'professor': 922,\n",
       " 'update': 923,\n",
       " 'appropriate': 924,\n",
       " 'faqs': 925,\n",
       " 'detected': 926,\n",
       " 'contacts': 927,\n",
       " 'enter': 928,\n",
       " 'editor': 929,\n",
       " 'alternative': 930,\n",
       " 'note': 931,\n",
       " 'mutation': 932,\n",
       " 'advertising': 933,\n",
       " 'chain': 934,\n",
       " 'views': 935,\n",
       " 'basic': 936,\n",
       " 'tissues': 937,\n",
       " 'blue': 938,\n",
       " 'membrane': 939,\n",
       " 'relationship': 940,\n",
       " 'numbers': 941,\n",
       " 'hepatitis': 942,\n",
       " 'essential': 943,\n",
       " 'presented': 944,\n",
       " 'whole': 945,\n",
       " 'ways': 946,\n",
       " 'acupuncture': 947,\n",
       " 'comparison': 948,\n",
       " 'metastatic': 949,\n",
       " 'disclosure': 950,\n",
       " 'example': 951,\n",
       " 'antibodies': 952,\n",
       " 'figures': 953,\n",
       " 'directions': 954,\n",
       " 'currently': 955,\n",
       " 'power': 956,\n",
       " 'taking': 957,\n",
       " 'recommended': 958,\n",
       " 'mobile': 959,\n",
       " 'approval': 960,\n",
       " 'middle': 961,\n",
       " 'innovative': 962,\n",
       " 'experiments': 963,\n",
       " 'technical': 964,\n",
       " 'inflammation': 965,\n",
       " 'incidence': 966,\n",
       " 'greater': 967,\n",
       " 'analyses': 968,\n",
       " 'chen': 969,\n",
       " 'literature': 970,\n",
       " 'advocacy': 971,\n",
       " 'continuing': 972,\n",
       " 'expected': 973,\n",
       " 'benefit': 974,\n",
       " 'zotero': 975,\n",
       " 'manage': 976,\n",
       " 'left': 977,\n",
       " 'aids': 978,\n",
       " 'partner': 979,\n",
       " 'indicated': 980,\n",
       " 'book': 981,\n",
       " 'selected': 982,\n",
       " 'hong': 983,\n",
       " 'johnson': 984,\n",
       " 'respiratory': 985,\n",
       " 'epithelial': 986,\n",
       " 'metabolic': 987,\n",
       " 'introduction': 988,\n",
       " 'reduce': 989,\n",
       " 'started': 990,\n",
       " 'success': 991,\n",
       " 'directors': 992,\n",
       " 'tumour': 993,\n",
       " 'stroke': 994,\n",
       " 'adverse': 995,\n",
       " 'scientists': 996,\n",
       " 'sharing': 997,\n",
       " 'statistical': 998,\n",
       " 'room': 999,\n",
       " 'characteristics': 1000,\n",
       " ...}"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#showing word index \n",
    "tokenizer.word_index"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The output labels are converted into one hot vectors."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "from keras.utils.np_utils import to_categorical\n",
    "y_tr=to_categorical(y_tr,num_classes=9)\n",
    "y_val=to_categorical(y_val,num_classes=9)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Model building\n",
    "\n",
    "Let us discuss about few terms and layers which are required prior to model building\n",
    "\n",
    "Keras is an open source deep learning library written in python. There are 2 ways of building models in keras i.e. Sequential API and Functional API\n",
    "\n",
    "**Sequential API**\n",
    "\n",
    "Here, we can add only one model in the same layer.  \n",
    "\n",
    "**Functional API**\n",
    "\n",
    "Here, we can add multiple models in the same layer.\n",
    "\n",
    "**keras embedding layer**\n",
    "\n",
    "Embedding Layer creates the embedding matrix which maps the integer to the embeddings. These embeddings are learnt during back propagation\n",
    "\n",
    "The below image gives the intuition of the keras embedding layer\n",
    "\n",
    "<img src=\"embeddings.JPG\">\n",
    "\n",
    "**Dropout**\n",
    "\n",
    "Dropout is a regularization technique which randomly dropouts neurons from the layer and the connections to these neurons are disabled and not involved in forward as well as the backward propagation\n",
    "\n",
    "**Recurrent dropout**\n",
    "\n",
    "This is used in Recurrent Neural Networks to dropout recurrent hidden units between the timesteps\n",
    "\n",
    "Now, let us build the sequential model for text classification\n",
    "\n",
    "### 1. LSTM Model\n",
    "\n",
    "Let's start with an LSTM model first and then we will build a GRU model with the same architecture and hyper-parameters to compare the performance of both the models.\n",
    "<img src=\"model.JPG\">"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "_________________________________________________________________\n",
      "Layer (type)                 Output Shape              Param #   \n",
      "=================================================================\n",
      "embedding_1 (Embedding)      (None, 500, 100)          46770400  \n",
      "_________________________________________________________________\n",
      "lstm_1 (LSTM)                (None, 300)               481200    \n",
      "_________________________________________________________________\n",
      "dense_1 (Dense)              (None, 64)                19264     \n",
      "_________________________________________________________________\n",
      "dense_2 (Dense)              (None, 9)                 585       \n",
      "=================================================================\n",
      "Total params: 47,271,449\n",
      "Trainable params: 47,271,449\n",
      "Non-trainable params: 0\n",
      "_________________________________________________________________\n",
      "None\n"
     ]
    }
   ],
   "source": [
    "from keras.models import Sequential\n",
    "from keras.layers import LSTM, Dense, Embedding, GRU\n",
    "from keras.callbacks import EarlyStopping, ModelCheckpoint\n",
    "import keras.backend as K\n",
    "K.clear_session()\n",
    "\n",
    "# LSTM model\n",
    "model=Sequential()\n",
    "model.add(Embedding(vocabulary,100,input_length=max_len,trainable=True, mask_zero=True)) \n",
    "model.add(LSTM(300,dropout=0.1, recurrent_dropout=0.2)) \n",
    "model.add(Dense(64,activation='relu')) \n",
    "model.add(Dense(9,activation='softmax')) \n",
    "print(model.summary()) "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Let us compile the model by specifying optimizer, loss and metrics\n",
    "\n",
    "Here, i am using categorical_crossentropy as loss function since it is-multi classification problem"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "model.compile(optimizer='adam', loss='categorical_crossentropy',metrics=[\"acc\"]) "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Callbacks**\n",
    "\n",
    "I define 2 callbacks here i.e. Early Stopping and Model Checkpoint\n",
    "\n",
    "**Early Stopping**\n",
    "\n",
    "This helps us in stopping the neural network at the right time. The training of neural network is stopped as the validation loss keeps increasing for some epochs which is specified using patience parameter\n",
    "\n",
    "**Model Checkpoint**\n",
    "\n",
    "The model obtained at the end of training is not the best model since the training of the model is stopped after the increase in validation loss.\n",
    "\n",
    "This helps in saving the best model at every epoch which can retrieved while making predictions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "es = EarlyStopping(monitor='val_loss', mode='min', verbose=1,patience=2)  \n",
    "mc=ModelCheckpoint('best_model.h5', monitor='val_loss', mode='min', save_best_only=True,verbose=1)  "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Let us fit the model to the training data and evaluate on hold out set."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Train on 37412 samples, validate on 16035 samples\n",
      "Epoch 1/100\n",
      "37412/37412 [==============================] - 76s 2ms/step - loss: 2.0234 - acc: 0.3693 - val_loss: 1.6284 - val_acc: 0.3655\n",
      "\n",
      "Epoch 00001: val_loss improved from inf to 1.62843, saving model to best_model.h5\n",
      "Epoch 2/100\n",
      "37412/37412 [==============================] - 72s 2ms/step - loss: 1.2358 - acc: 0.5792 - val_loss: 0.8153 - val_acc: 0.7280\n",
      "\n",
      "Epoch 00002: val_loss improved from 1.62843 to 0.81533, saving model to best_model.h5\n",
      "Epoch 3/100\n",
      "37412/37412 [==============================] - 73s 2ms/step - loss: 0.6236 - acc: 0.7906 - val_loss: 0.4976 - val_acc: 0.8248\n",
      "\n",
      "Epoch 00003: val_loss improved from 0.81533 to 0.49762, saving model to best_model.h5\n",
      "Epoch 4/100\n",
      "37412/37412 [==============================] - 73s 2ms/step - loss: 0.4085 - acc: 0.8629 - val_loss: 0.4093 - val_acc: 0.8551\n",
      "\n",
      "Epoch 00004: val_loss improved from 0.49762 to 0.40929, saving model to best_model.h5\n",
      "Epoch 5/100\n",
      "37412/37412 [==============================] - 73s 2ms/step - loss: 0.3293 - acc: 0.8883 - val_loss: 0.3566 - val_acc: 0.8790\n",
      "\n",
      "Epoch 00005: val_loss improved from 0.40929 to 0.35663, saving model to best_model.h5\n",
      "Epoch 6/100\n",
      "37412/37412 [==============================] - 73s 2ms/step - loss: 0.2780 - acc: 0.9063 - val_loss: 0.3387 - val_acc: 0.8862\n",
      "\n",
      "Epoch 00006: val_loss improved from 0.35663 to 0.33866, saving model to best_model.h5\n",
      "Epoch 7/100\n",
      "37412/37412 [==============================] - 74s 2ms/step - loss: 0.2387 - acc: 0.9218 - val_loss: 0.3966 - val_acc: 0.8611\n",
      "\n",
      "Epoch 00007: val_loss did not improve from 0.33866\n",
      "Epoch 8/100\n",
      "37412/37412 [==============================] - 74s 2ms/step - loss: 0.2634 - acc: 0.9149 - val_loss: 0.3313 - val_acc: 0.8949\n",
      "\n",
      "Epoch 00008: val_loss improved from 0.33866 to 0.33130, saving model to best_model.h5\n",
      "Epoch 9/100\n",
      "37412/37412 [==============================] - 74s 2ms/step - loss: 0.2027 - acc: 0.9337 - val_loss: 0.3134 - val_acc: 0.9003\n",
      "\n",
      "Epoch 00009: val_loss improved from 0.33130 to 0.31340, saving model to best_model.h5\n",
      "Epoch 10/100\n",
      "37412/37412 [==============================] - 74s 2ms/step - loss: 0.1826 - acc: 0.9404 - val_loss: 0.2959 - val_acc: 0.9074\n",
      "\n",
      "Epoch 00010: val_loss improved from 0.31340 to 0.29587, saving model to best_model.h5\n",
      "Epoch 11/100\n",
      "37412/37412 [==============================] - 73s 2ms/step - loss: 0.1640 - acc: 0.9450 - val_loss: 0.2882 - val_acc: 0.9096\n",
      "\n",
      "Epoch 00011: val_loss improved from 0.29587 to 0.28822, saving model to best_model.h5\n",
      "Epoch 12/100\n",
      "37412/37412 [==============================] - 73s 2ms/step - loss: 0.1503 - acc: 0.9509 - val_loss: 0.2973 - val_acc: 0.9086\n",
      "\n",
      "Epoch 00012: val_loss did not improve from 0.28822\n",
      "Epoch 13/100\n",
      "37412/37412 [==============================] - 74s 2ms/step - loss: 0.1465 - acc: 0.9513 - val_loss: 0.2834 - val_acc: 0.9120\n",
      "\n",
      "Epoch 00013: val_loss improved from 0.28822 to 0.28335, saving model to best_model.h5\n",
      "Epoch 14/100\n",
      "37412/37412 [==============================] - 74s 2ms/step - loss: 0.1312 - acc: 0.9559 - val_loss: 0.2882 - val_acc: 0.9128\n",
      "\n",
      "Epoch 00014: val_loss did not improve from 0.28335\n",
      "Epoch 15/100\n",
      "37412/37412 [==============================] - 73s 2ms/step - loss: 0.1270 - acc: 0.9578 - val_loss: 0.2910 - val_acc: 0.9138\n",
      "\n",
      "Epoch 00015: val_loss did not improve from 0.28335\n",
      "Epoch 00015: early stopping\n"
     ]
    }
   ],
   "source": [
    "history = model.fit(np.array(x_tr),np.array(y_tr),batch_size=1200,epochs=100,validation_data=(np.array(x_val),np.array(y_val)),verbose=1,callbacks=[es,mc])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Diagnostic Plots**\n",
    "\n",
    "The diagnostic plots helps in understanding the performance of the model over time"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x7f224d6f8e48>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from matplotlib import pyplot\n",
    "pyplot.plot(history.history['loss'], label='train')\n",
    "pyplot.plot(history.history['val_loss'], label='test')\n",
    "pyplot.legend()\n",
    "pyplot.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "- From the above plot, we can infer that the validation loss has increased after epoch 8. Hence, the training is stopped at the end of epoch 10. \n",
    "\n",
    "- We can also observe that model obtained after epoch 10 is not the best model since the validation loss has increased. Hence, we make use of model checkpoint.\n",
    "- Let us retrieve the best model and make predictions on the validation data."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "from keras.models import load_model\n",
    "model = load_model('best_model.h5')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "             precision    recall  f1-score   support\n",
      "\n",
      "          0       0.99      0.97      0.98       868\n",
      "          1       0.91      0.89      0.90      1408\n",
      "          2       0.99      0.99      0.99      1364\n",
      "          3       0.96      0.87      0.91       389\n",
      "          4       0.84      0.87      0.85      2425\n",
      "          5       0.88      0.90      0.89      5241\n",
      "          6       0.93      0.86      0.89      1556\n",
      "          7       0.95      0.94      0.95      2257\n",
      "          8       1.00      1.00      1.00       527\n",
      "\n",
      "avg / total       0.91      0.91      0.91     16035\n",
      "\n"
     ]
    }
   ],
   "source": [
    "from sklearn.metrics import classification_report\n",
    "\n",
    "y_pred=model.predict_classes(np.array(x_val))\n",
    "y_true = np.argmax(y_val, axis=1)\n",
    "print(classification_report(y_true,y_pred))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2. GRU Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "_________________________________________________________________\n",
      "Layer (type)                 Output Shape              Param #   \n",
      "=================================================================\n",
      "embedding_1 (Embedding)      (None, 500, 100)          46770400  \n",
      "_________________________________________________________________\n",
      "gru_1 (GRU)                  (None, 300)               360900    \n",
      "_________________________________________________________________\n",
      "dense_1 (Dense)              (None, 64)                19264     \n",
      "_________________________________________________________________\n",
      "dense_2 (Dense)              (None, 9)                 585       \n",
      "=================================================================\n",
      "Total params: 47,151,149\n",
      "Trainable params: 47,151,149\n",
      "Non-trainable params: 0\n",
      "_________________________________________________________________\n",
      "None\n"
     ]
    }
   ],
   "source": [
    "from keras.models import Sequential\n",
    "from keras.layers import LSTM, Dense, Embedding, GRU\n",
    "from keras.callbacks import EarlyStopping, ModelCheckpoint\n",
    "import keras.backend as K\n",
    "K.clear_session()\n",
    "\n",
    "# GRU model\n",
    "model2=Sequential()\n",
    "model2.add(Embedding(vocabulary,100,input_length=max_len,trainable=True, mask_zero=True)) \n",
    "model2.add(GRU(300,dropout=0.1, recurrent_dropout=0.2)) \n",
    "model2.add(Dense(64,activation='relu')) \n",
    "model2.add(Dense(9,activation='softmax')) \n",
    "print(model2.summary())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Train on 37412 samples, validate on 16035 samples\n",
      "Epoch 1/100\n",
      "37412/37412 [==============================] - 50s 1ms/step - loss: 2.0347 - acc: 0.3760 - val_loss: 1.7656 - val_acc: 0.4732\n",
      "\n",
      "Epoch 00001: val_loss improved from inf to 1.76563, saving model to best_model_gru.h5\n",
      "Epoch 2/100\n",
      "37412/37412 [==============================] - 48s 1ms/step - loss: 1.3873 - acc: 0.5569 - val_loss: 0.9887 - val_acc: 0.7026\n",
      "\n",
      "Epoch 00002: val_loss improved from 1.76563 to 0.98873, saving model to best_model_gru.h5\n",
      "Epoch 3/100\n",
      "37412/37412 [==============================] - 48s 1ms/step - loss: 0.7410 - acc: 0.7788 - val_loss: 0.5766 - val_acc: 0.8148\n",
      "\n",
      "Epoch 00003: val_loss improved from 0.98873 to 0.57664, saving model to best_model_gru.h5\n",
      "Epoch 4/100\n",
      "37412/37412 [==============================] - 48s 1ms/step - loss: 0.4682 - acc: 0.8534 - val_loss: 0.4609 - val_acc: 0.8429\n",
      "\n",
      "Epoch 00004: val_loss improved from 0.57664 to 0.46089, saving model to best_model_gru.h5\n",
      "Epoch 5/100\n",
      "37412/37412 [==============================] - 48s 1ms/step - loss: 0.3759 - acc: 0.8748 - val_loss: 0.4120 - val_acc: 0.8593\n",
      "\n",
      "Epoch 00005: val_loss improved from 0.46089 to 0.41198, saving model to best_model_gru.h5\n",
      "Epoch 6/100\n",
      "37412/37412 [==============================] - 48s 1ms/step - loss: 0.3203 - acc: 0.8905 - val_loss: 0.3785 - val_acc: 0.8694\n",
      "\n",
      "Epoch 00006: val_loss improved from 0.41198 to 0.37847, saving model to best_model_gru.h5\n",
      "Epoch 7/100\n",
      "37412/37412 [==============================] - 48s 1ms/step - loss: 0.2671 - acc: 0.9099 - val_loss: 0.3442 - val_acc: 0.8859\n",
      "\n",
      "Epoch 00007: val_loss improved from 0.37847 to 0.34417, saving model to best_model_gru.h5\n",
      "Epoch 8/100\n",
      "37412/37412 [==============================] - 48s 1ms/step - loss: 0.2145 - acc: 0.9307 - val_loss: 0.3145 - val_acc: 0.9014\n",
      "\n",
      "Epoch 00008: val_loss improved from 0.34417 to 0.31449, saving model to best_model_gru.h5\n",
      "Epoch 9/100\n",
      "37412/37412 [==============================] - 48s 1ms/step - loss: 0.1592 - acc: 0.9522 - val_loss: 0.2977 - val_acc: 0.9121\n",
      "\n",
      "Epoch 00009: val_loss improved from 0.31449 to 0.29767, saving model to best_model_gru.h5\n",
      "Epoch 10/100\n",
      "37412/37412 [==============================] - 49s 1ms/step - loss: 0.1226 - acc: 0.9639 - val_loss: 0.2924 - val_acc: 0.9156\n",
      "\n",
      "Epoch 00010: val_loss improved from 0.29767 to 0.29239, saving model to best_model_gru.h5\n",
      "Epoch 11/100\n",
      "37412/37412 [==============================] - 49s 1ms/step - loss: 0.1004 - acc: 0.9694 - val_loss: 0.3026 - val_acc: 0.9175\n",
      "\n",
      "Epoch 00011: val_loss did not improve from 0.29239\n",
      "Epoch 12/100\n",
      "37412/37412 [==============================] - 48s 1ms/step - loss: 0.0823 - acc: 0.9752 - val_loss: 0.3072 - val_acc: 0.9176\n",
      "\n",
      "Epoch 00012: val_loss did not improve from 0.29239\n",
      "Epoch 00012: early stopping\n"
     ]
    }
   ],
   "source": [
    "# compile model\n",
    "model2.compile(optimizer='adam', loss='categorical_crossentropy',metrics=[\"acc\"]) \n",
    "\n",
    "# checkpoints \n",
    "es = EarlyStopping(monitor='val_loss', mode='min', verbose=1,patience=2)  \n",
    "mc=ModelCheckpoint('best_model_gru.h5', monitor='val_loss', mode='min', save_best_only=True,verbose=1)  \n",
    "\n",
    "# model history\n",
    "history2 = model2.fit(np.array(x_tr),np.array(y_tr),batch_size=1200,epochs=100,validation_data=(np.array(x_val),np.array(y_val)),verbose=1,callbacks=[es,mc])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "- Let us retrieve the best model and make predictions on the validation data."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "             precision    recall  f1-score   support\n",
      "\n",
      "          0       0.99      0.95      0.97       868\n",
      "          1       0.90      0.88      0.89      1408\n",
      "          2       0.99      0.99      0.99      1364\n",
      "          3       0.92      0.86      0.89       389\n",
      "          4       0.86      0.87      0.87      2425\n",
      "          5       0.90      0.92      0.91      5241\n",
      "          6       0.94      0.87      0.90      1556\n",
      "          7       0.93      0.94      0.93      2257\n",
      "          8       0.99      1.00      0.99       527\n",
      "\n",
      "avg / total       0.92      0.92      0.92     16035\n",
      "\n"
     ]
    }
   ],
   "source": [
    "from keras.models import load_model\n",
    "\n",
    "# load best model\n",
    "model = load_model('best_model_gru.h5')\n",
    "\n",
    "# make predictions\n",
    "from sklearn.metrics import classification_report\n",
    "\n",
    "y_pred=model.predict_classes(np.array(x_val))\n",
    "y_true = np.argmax(y_val, axis=1)\n",
    "print(classification_report(y_true,y_pred))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "We have seen how to build deep learning model for multi classification problem by covering all the necessary details of implementation in python using keras"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3. Comparison: LSTM vs GRU\n",
    "\n",
    " - GRU takes approx. 40% of lesser training time for similar performance.\n",
    " - LSTM might be good for more complex problems like Machine Translation.\n",
    " - GRU should be preferred when experimenting."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
